Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.
2025 · 1st Quarter (Jan 1 - Mar 31)
SAVE RARE TREATMENTS TASK FORCE
Filed by LEAVITT PARTNERS, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 22, 2025
- Income
- $40,000.00
- Expenses
- Not reported
- Registrant
- LEAVITT PARTNERS, LLC
- Filing UUID
- be1514fa-ef87-4a4a-9173-ec6a54ffc757
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.